This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Robert F. Asarnow, PhD; Stephen R. Marder, MD; Jim Mintz, PhD; Theodore Van Putten, MD; Karin E. Zimmerman, MA

Arch Gen Psychiatry. 1988;45(9):822-826.

Abstract
• Thirty-six stabilized schizophrenic outpatients were randomly assigned to receive either 5 or 25 mg of fluphenazine decanoate biweekly and were followed up for two years. The best and worst outcomes were found in groups with good or poor information-processing abilities (as measured by a partial-report span-of-apprehension task) given the same 25-mg dose of fluphenazine decanoate. The 86% two-year survival rate of the patients with poor span performance was considerably better, while the 44% one-year and the 21% two-year survival rates of patients with good span performance were considerably lower than previously reported survival rates for schizophrenic patients receiving a conventional dose of fluphenazine. The significant correlations in a patient's span performance for periods up to one year were consistent with the hypothesis that this task taps processes associated with vulnerability to schizophrenic disorder.

Author Affiliations
From the Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Los Angeles (Drs Asarnow, Marder, Mintz, and Van Putten), and the West Los Angeles Veterans Administration Medical Center, Brentwood Division (Drs Marder, Mintz, and Van Putten and Ms Zimmerman).

Footnotes
Accepted for publication Dec 14, 1987.

Reprint requests to Department of Psychiatry and Behavioral Sciences, UCLA School of Medicine, Neuropsychiatric Institute, 760 Westwood Plaza, Los Angeles, CA 90024 (Dr Asarnow).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?